Nasal corticosteroids presents no ocular dangers in children

Article

Intermittent nasal corticosteroids do not cause ocular side effects such as cataract, glaucoma, corneal ectasia or abnormal tear function in children.

Intermittent nasal corticosteroids do not cause ocular side effects such as cataract, glaucoma, corneal ectasia or abnormal tear function in children, claims a study in Journal of Pediatric Ophthalmology & Strabismus.

A team managed by Dr Emin Ozayaka, Vakif Gureba Education and Research Hospital, Istanbul, Turkey, investigated a study group of 150 children who were administered intermittent intranasal budesonide for over two years. There were also 90 newly diagnosed allergic rhinitis patients included in the study who were not administered any treatment (control group).

The factors that were compared between the two groups were central corneal thickness, Schirmer test results, visual acuity, intraocular pressure, cataract formation, keratometry and tear break-up time.

The average steroid dosage was 93.3 ± 7.0 µg per day and 42.2 ± 3.2 g being the total steroid used during treatment. Of the 150 children included in the study group cataract formation, corneal ectasia, ocular hypertension and glaucoma were not found. Also, there was no correlation between the study group patients and total steroid dosage.

Treating children suffering from allergic rhinitis with intermittent intranasal budesonide at an average dose of 100 µg does not cause ocular defects.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.